Find the Thesis HereWGS · NASDAQ
Can Test-Mix Gains Become Durable Diagnostic Economics?
A published thesis testing whether genomic volume, interpretation quality and reimbursement can convert a rare-disease data advantage into durable profitability.
PublishedUpdated August 7, 2026
Open thesis →Q2 2026 snapshotCompany reported
Revenue$114.4M11% year over year
Exome + genome volume30,78532% year over year
Adjusted gross margin70%68% GAAP
2026 revenue guide$475–490M≥30% volume growth
Source: GeneDx Q2 2026 results. Figures are not forecasts or recommendations.